Poland· PL-100433990
Recarbrio
A imipenem, cilastatin and relebactam product containing imipenemum + cilastatinum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Imipenem, cilastatin and relebactam is registered in 11 of 19 countries.
Countries holding a registration under ATC J01DH56 (imipenem, cilastatin and relebactam), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Imipenem, cilastatin and relebactam · ATC J01DH56
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Imipenemum + Cilastatinum
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- J01DH56
- ATC class
- Imipenem, cilastatin and relebactam
- Defined daily dose
- 2 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin00191778022957
- gtin00191778023459
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J01DH56
Imipenem, cilastatin and relebactam, as other registers publish it.
- NorwayRecarbrioMSD
- IcelandRecarbrioMerck Sharp & Dohme B.V.*
- DenmarkRecarbrioMerck Sharp & Dohme B.V.
- NorwayRecarbrioMerck Sharp & Dohme B.V. (1)
- FinlandRecarbrioMerck Sharp & Dohme B.V.
- CzechiaRECARBRIOMerck Sharp & Dohme B.V., Haarlem
- United StatesRECARBRIOMerck Sharp & Dohme LLC
- BelgiumRecarbrio 500 mg - 500 mg - 250 mgMerck Sharp & Dohme
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/741074ca-3355-46aa-bb64-d024c5b15919 GET /v1/drugs/741074ca-3355-46aa-bb64-d024c5b15919?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "500 mg/500 mg/250 mg",
"packaging": "00191778022957 ¦ Rpz ¦ EU/1/19/1420/001 ¦ 135949\n25 fiol. \n¦ UR/Z/4c/319/25 - 00191778023459",
"substance": "Imipenemum 500 mg + Cilastatinum 500 mg",
"common_name": "Imipenemum + Cilastatinum",
"pl_product_id": "100433990",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about imipenem, cilastatin and relebactam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.